Dynasil Corporation of America (DYSL) 10-Q 11 Feb 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Dec. 31, 2015	Feb. 05, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	DYNASIL CORP OF AMERICA
Entity Central Index Key	30,831
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	DYSL
Entity Common Stock, Shares Outstanding		16,730,231

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Current Assets
Cash and cash equivalents	$ 1,101,000	$ 1,295,000
Accounts receivable, net of allowances of $168,000 at December 31, 2015 and September 30, 2015, respectively	4,444,000	3,382,000
Costs in excess of billings and unbilled receivables	1,288,000	1,518,000
Inventories, net of reserves	3,252,000	3,066,000
Prepaid expenses and other current assets	1,152,000	1,125,000
Total current assets	11,237,000	10,386,000
Property, Plant and Equipment, net	7,048,000	6,662,000
Other Assets
Intangibles, net	1,197,000	1,225,000
Goodwill	6,094,000	6,131,000
Security deposits	60,000	58,000
Total other assets	7,351,000	7,414,000
Total Assets	25,636,000	24,462,000
Current Liabilities
Current portion of long-term debt	2,503,000	1,567,000
Capital lease obligations, current	89,000	76,000
Convertible notes	2,540,000	2,123,000
Accounts payable	1,901,000	1,886,000
Deferred revenue	245,000	109,000
Accrued expenses and other liabilities	2,342,000	2,650,000
Total current liabilities	9,620,000	8,411,000
Long-term Liabilities
Long-term debt, net of current portion	1,129,000	1,288,000
Capital lease obligations, net of current portion	118,000	43,000
Deferred tax liability	214,000	242,000
Other long-term liabilities	49,000	50,000
Total long-term liabilities	1,510,000	1,623,000
Stockholders' Equity
Common Stock, $0.0005 par value, 40,000,000 shares authorized, 17,458,249 and 17,368,738 shares issued, 16,648,089 and 16,558,578 shares outstanding at December 31, 2015 and September 30, 2015, respectively.	9,000	9,000
Additional paid in capital	19,773,000	19,650,000
Accumulated other comprehensive income (loss)	(4,000)	110,000
Accumulated deficit	(4,061,000)	(4,167,000)
Less 810,160 shares of treasury stock - at cost	(986,000)	(986,000)
Total Dynasil stockholders' equity	14,731,000	14,616,000
Noncontrolling interest	(225,000)	(188,000)
Total stockholders' equity	14,506,000	14,428,000
Total Liabilities and Stockholders' Equity	$ 25,636,000	$ 24,462,000

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Allowance for doubtful accounts (in dollars)	$ 168,000	$ 168,000
Common stock, par value (in dollars per share)	$ 0.0005	$ 0.0005
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	17,458,249	17,368,738
Common stock, shares outstanding	16,648,089	16,558,578
Treasury stock, shares	810,160	810,160

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Net revenue	$ 11,204,000	$ 9,611,000
Cost of revenue	7,239,000	6,018,000
Gross profit	3,965,000	3,593,000
Operating expenses:
Sales and marketing	341,000	365,000
Research and development	491,000	375,000
General and administrative	2,973,000	3,467,000
Gain on sale of assets	(4,000)	(185,000)
Total operating expenses	3,801,000	4,022,000
Income (loss) from operations	164,000	(429,000)
Interest expense, net	59,000	125,000
Income (loss) before taxes	105,000	(554,000)
Income tax (credit)	36,000	3,000
Net income (loss)	69,000	(557,000)
Less: Net loss attributable to noncontrolling interest	(37,000)	(24,000)
Net income (loss) attributable to common stockholders	106,000	(533,000)
Net income (loss)	69,000	(557,000)
Other comprehensive income (loss):
Increase (decrease) in pension liability	0	318,000
Foreign currency translation	(114,000)	(194,000)
Total comprehensive loss	$ (45,000)	$ (433,000)
Basic net income (loss) per common share (in dollars per share)	$ 0.01	$ (0.03)
Diluted net income (loss) per common share (in dollars per share)	$ 0.01	$ (0.03)
Weighted average shares outstanding
Basic (in shares)	16,551,197	16,300,902
Diluted (in shares)	16,578,634	16,300,902

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - 3 months ended Dec. 31, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance at Sep. 30, 2015	$ 14,428,000	$ 9,000	$ 19,650,000	$ 110,000	$ (4,167,000)	$ (986,000)	$ (188,000)
Balance (in shares) at Sep. 30, 2015		17,368,738				810,160
Issuance of shares of common stock under employee stock purchase plan	4,000	$ 0	4,000	0	0	$ 0	0
Issuance of shares of common stock under employee stock purchase plan (in shares)		2,295				0
Stock-based compensation costs	119,000	$ 0	119,000	0	0	$ 0	0
Stock-based compensation costs (in shares)		87,216				0
Foreign currency translation adjustment	(114,000)	$ 0	0	(114,000)	0	$ 0	0
Net income (loss)	69,000	0	0	0	106,000	0	(37,000)
Balance at Dec. 31, 2015	$ 14,506,000	$ 9,000	$ 19,773,000	$ (4,000)	$ (4,061,000)	$ (986,000)	$ (225,000)
Balance (in shares) at Dec. 31, 2015		17,458,249				810,160

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ 69,000	$ (557,000)
Adjustments to reconcile net income (loss) to net cash:
Stock compensation expense	119,000	65,000
Foreign exchange loss (gain)	26,000	(23,000)
Gain on sale of assets	(4,000)	(185,000)
Depreciation and amortization	325,000	293,000
Pension expense	0	318,000
Other	16,000	(35,000)
Other changes in assets and libilities:
Accounts receivable, net	(1,101,000)	(79,000)
Inventories	(218,000)	12,000
Costs in excess of billings and unbilled receivables	231,000	(56,000)
Prepaid expenses and other assets	(32,000)	(469,000)
Accounts payable	34,000	(360,000)
Accrued expenses and other liabilities	(303,000)	(438,000)
Deferred revenue	136,000	(76,000)
Net cash from operating activities	(702,000)	(1,590,000)
Cash flows from investing activities:
Proceeds from sale of assets	4,000	244,000
Purchases of property, plant and equipment	(603,000)	(244,000)
Net cash from investing activities	(599,000)	0
Cash flows from financing activities:
Proceeds from issuance of common stock	4,000	3,000
Net proceeds from issuance of convertible notes	390,000	18,000
Principal payments on capital leases	(46,000)	(33,000)
Proceeds from short and long-term debt	5,037,000	300,000
Payments on long-term debt	(4,264,000)	(19,000)
Net cash from financing activities	1,121,000	269,000
Effect of exchange rates on cash and cash equivalents	(14,000)	(17,000)
Net change in cash and cash equivalents	(194,000)	(1,338,000)
Cash and cash equivalents, beginning	1,295,000	3,842,000
Cash and cash equivalents, ending	1,101,000	2,504,000
Non cash activities:
Assets purchased under capital leases	$ 134,000	$ 73,000

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 1 - Basis of Presentation The accompanying consolidated balance sheet as of December 31, 2015, the consolidated statements of operations and comprehensive income (loss) for the three months ended December 31, 2015 and 2014, changes in stockholders’ equity for the three months ended December 31, 2015 and cash flows for the three months ended December 31, 2015 and 2014 of Dynasil Corporation of America and subsidiaries (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Certain prior year balances have been reclassified to conform to the current year presentation. These reclassifications did not affect previously reported net loss or stockholders’ deficit. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. The preparation of our unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2015 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission. The Company considers events or transactions that have occurred after the unaudited consolidated balance sheet date of December 31, 2015, but prior to the filing of the unaudited consolidated financial statements with the SEC on this Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Adoption of Accounting Pronounc

Adoption of Accounting Pronouncements	3 Months Ended
	Dec. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	Note 2 – Adoption of Accounting Pronouncements Effective October 1, 2015, the Company early adopted the guidance issued in Accounting Standards Update 2015-03, Interest – Imputation of Interest (Topic 835) (“ASU 2015-03”) to simplify the presentation of debt issuance costs. This standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The Company adopted this guidance on a retrospective basis, wherein the balance sheet of each individual period presented was adjusted to reflect the period-specific effects of applying the new guidance. As a result of the adoption of ASU 2015-03, $ 12,000 Effective for the reporting period beginning October 1, 2015, the Company early adopted the guidance issued in Accounting Standards Update 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”) which simplifies the presentation of deferred income taxes. ASU 2015-17 concludes that deferred tax liabilities and assets should be classified as noncurrent in a classified statement of financial position. The Company adopted this guidance on a retrospective basis, wherein the balance sheet of each individual period presented was adjusted to reflect the period-specific effects of applying the new guidance. The adoption of this ASU did not have a material impact on the Company’s financial statements.

Acquisitions and Divestitures

Acquisitions and Divestitures	3 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Note 3 – Acquisitions and Divestitures In the three months ended December 31, 2014, the Company recorded a gain of $ 0.2

Xcede Technologies, Inc. Joint

Xcede Technologies, Inc. Joint Venture	3 Months Ended
	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 4 – Xcede Technologies, Inc. Joint Venture In October, 2013, the Company formed Xcede Technologies, Inc. (“Xcede”), a joint venture with Mayo Clinic, in order to spin out and separately fund the development of its tissue sealant technology, which formerly comprised the majority of its biomedical segment. Xcede has raised approximately $ 2.4 5 Upon the closing of a capital stock financing raising at least $ 3.0 20 5 Xcede’s common stock is 90 On January 6, 2016, Xcede announced that it has signed three agreements with Cook Biotech Inc. of West Lafayette, IN including a Development Agreement, a License Agreement and a Supply Agreement in connection with the development, regulatory approval and production of Xcede’s resorbable hemostatic patch.

Inventories

Inventories	3 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 5 - Inventories Inventories, net of reserves, consists of the following: December 31, September 30, 2015 2015 Raw Materials $ 1,883,000 $ 1,828,000 Work-in-Process 847,000 862,000 Finished Goods 522,000 376,000 $ 3,252,000 $ 3,066,000

Intangible Assets

Intangible Assets	3 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 – Intangible Assets Intangible assets at December 31, 2015 and September 30, 2015 consist of the following: Useful Gross Accumulated December 31, 2015 Life (years) Amount Amortization Net Acquired Customer Base 5 to 15 $ 807,000 $ 473,000 $ 334,000 Know How 15 512,000 256,000 256,000 Trade Names Indefinite 310,000 - 310,000 Patents 20 254,000 2,000 252,000 Biomedical Technologies 5 260,000 215,000 45,000 $ 2,143,000 $ 946,000 $ 1,197,000 Useful Gross Accumulated September 30, 2015 Life (years) Amount Amortization Net Acquired Customer Base 5 to 15 $ 824,000 $ 464,000 $ 360,000 Know How 15 512,000 248,000 264,000 Trade Names Indefinite 318,000 - 318,000 Patents 20 223,000 - 223,000 Biomedical Technologies 5 260,000 200,000 60,000 $ 2,137,000 $ 912,000 $ 1,225,000 Amortization expense for the three months ended December 31, 2015 and 2014 was $ 44,000 43,000 Estimated amortization expense for each of the next five fiscal years and thereafter is as follows: 2016 (9 months) 2017 2018 2019 2020 Thereafter Total Acquired Customer Base $ 60,000 $ 80,000 $ 80,000 $ 80,000 $ 34,000 $ - $ 334,000 Know How 26,000 34,000 34,000 34,000 34,000 94,000 256,000 Patents 5,000 6,000 6,000 6,000 6,000 61,000 90,000 Biomedical Technologies 45,000 - - - - - 45,000 $ 136,000 $ 120,000 $ 120,000 $ 120,000 $ 74,000 $ 155,000 $ 725,000

Goodwill

Goodwill	3 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	Note 7 – Goodwill Goodwill is subject to an annual impairment test. The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests. These include: · A significant adverse long term outlook for any of its industries; · An adverse finding or rejection from a regulatory body involved in new product regulatory approvals; · Failure of an anticipated commercialization of a product or product line; · Unanticipated competition or the introduction of a disruptive technology; · The testing for recoverability under the Impairment or Disposal of Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit; · A loss of key personnel; and · An expectation that a reporting unit carrying goodwill, or a significant portion of a reporting unit, will be sold or otherwise disposed of. There were no changes, aside from foreign exchange rate fluctuations, in the carrying value of goodwill during the three months ended December 31, 2015.

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	3 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 8 – Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing the net income or loss attributable to common shares by the weighted average number of common shares. Diluted earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible preferred stock and other potential dilutive common shares outstanding during the periods. For purposes of computing diluted earnings per share for the three months ended December 31, 2015, no common stock options were included in the calculation of dilutive shares as all of the 58,212 common stock options outstanding had exercise prices above the applicable quarterly average market price per share and their inclusion would be anti-dilutive. For the three months ended December 31, 2014, no common share equivalents related to stock options were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would be anti-dilutive. For the three months ended December 31, 2015, 27,437 shares of common stock related to restricted stock were included in the denominator used to calculate diluted earnings per share. For the three months ended December 31, 2014, no common share equivalents related to restricted stock were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would be anti-dilutive. The computation of the weighted shares outstanding for the three months ended December 31 is as follows: December 31, 2015 December 31, 2014 Weighted average shares outstanding Basic 16,551,197 16,300,902 Effect of dilutive securities Stock Options - - Restricted Stock 27,437 - Dilutive Average Shares Outstanding 16,578,634 16,300,902

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 - Stock Based Compensation The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model. The expected volatility was determined with reference to the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted represents the period of time that the options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate in effect at the time of grant. The dividend yield is expected to be zero because historically the Company has not paid dividends on common stock. The Company’s Xcede joint venture adopted an Equity Incentive Plan in 2013 which provides for, among other incentives, the granting to officers, directors, employees and consultants options to purchase shares in Xcede’s common stock. The options granted generally vest over a 3 Three Months Ended Three Months Ended Stock Compensation Expense December 31, 2015 December 31, 2014 Stock Grants $ 83,000 $ 57,000 Restricted Stock Grants 8,000 7,000 Option Grants 6,000 - Employee Stock Purchase Plan 1,000 1,000 Subsidiary Option Grants 21,000 - Total $ 119,000 $ 65,000 At December 31, 2015 there was approximately $ 86,000 Restricted Stock Grants Restricted Stock Activity for the Three Months ended Weighted-Average December 31, 2015 Shares Grant-Date Fair Value Nonvested at September 30, 2015 27,000 $ 1.04 Granted 40,000 1.70 Vested - - Cancelled - - Nonvested at December 31, 2015 67,000 $ 1.43 Stock Option Grants During the three months ended December 31, 2015, no Dynasil stock options were granted. Weighted Average Weighted Average Options Exercise Price per Remain Contractual Outstanding Share Term (in Years) Balance at September 30, 2015 58,212 $ 2.28 1.96 Outstanding and exercisable at September 30, 2015 58,212 $ 2.28 1.96 Granted - - Exercised - - Cancelled - - Balance at December 31, 2015 58,212 $ 2.28 1.71 Outstanding and exercisable at December 31, 2015 58,212 $ 2.28 1.71 Subsidiary Stock Option Grants During the three months ended December 31, 2015, 75,000 1.00 Expected term in years 10 years Risk-free interest rate 2.05 % Expected volatility 82.42 % Expected dividend yield 0.00 % Weighted Average Weighted Average Options Exercise Price per Remain Contractual Outstanding Share Term (in Years) Balance at September 30, 2015 780,258 $ 1.00 8.85 Outstanding and exercisable at September 30, 2015 180,293 $ 1.00 8.50 Granted 75,000 $ 1.00 Exercised - - Cancelled (35,000) $ 1.00 Balance at December 31, 2015 820,258 $ 1.00 8.70 Outstanding and exercisable at December 31, 2015 201,512 $ 1.00 8.21 At December 31, 2015, the Company’s Xcede joint venture had $ 195,000 82,000

Segment, Customer and Geographi

Segment, Customer and Geographical Reporting	3 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 10 – Segment, Customer and Geographical Reporting Segment Financial Information Dynasil’s business is comprised of three segments: optics (“Optics”), contract research (“Contract Research”) and biomedical (“Biomedical”). The Company’s Instruments segment was substantially disposed of in the first quarter of fiscal 2014, has had no subsequent operations and had no remaining assets as of December 31, 2015. Consequently, it is no longer reported as a separate segment. At December 31, 2014, the Company had approximately $ 0.3 Within these segments, there is a segregation of reportable units based upon the organizational structure used to evaluate performance and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with that structure. The Optics segment manufactures optical materials, components and coatings. The Contract Research segment is one of the largest small business participants in U.S. government-funded research. The Biomedical segment, through Xcede Technologies, Inc., a majority owned, joint venture, is focused on developing a tissue sealant technology though no assurance can be given that this technology will become successfully commercialized. Results of Operations for the Three Months Ended December 31, 2015 Contract Optics Research Biomedical Total Revenue $ 6,214,000 $ 4,990,000 $ - $ 11,204,000 Gross Profit 2,110,000 1,855,000 - 3,965,000 GM % 34.0 % 37.2 % - 35.4 % SG&A 1,751,000 1,706,000 348,000 3,805,000 Gain on sale of assets 4,000 - - 4,000 Operating Income (Loss) 363,000 149,000 (348,000) 164,000 Depreciation and Amortization 228,000 80,000 17,000 325,000 Capital expenditures 565,000 7,000 31,000 603,000 Intangibles, Net 644,000 256,000 297,000 1,197,000 Goodwill 1,155,000 4,939,000 - 6,094,000 Total Assets $ 16,506,000 $ 8,273,000 $ 857,000 $ 25,636,000 Results of Operations for the Three Months Ended December 31, 2014 Contract Optics Research Biomedical Total Revenue $ 4,948,000 $ 4,663,000 $ - $ 9,611,000 Gross Profit 1,495,000 2,098,000 - 3,593,000 GM % 30.2 % 45.0 % - 37.4 % SG&A 2,091,000 1,881,000 235,000 4,207,000 Gain on sale of assets 185,000 - - 185,000 Operating Income (Loss) (410,000) 216,000 (235,000) (429,000) Depreciation and Amortization 204,000 74,000 15,000 293,000 Capital expenditures 244,000 - - 244,000 Intangibles, Net 752,000 290,000 229,000 1,271,000 Goodwill 1,232,000 4,939,000 - 6,171,000 Total Assets $ 15,419,000 $ 9,036,000 $ 922,000 $ 25,377,000 Customer Financial Information For the three months ended December 31, 2015, one customer in the Optics segment represented more than 10% of the total segment revenue. For the three months ended December 31, 2014, the single largest customer in the Optics segment made up 21 9 For the three months ended December 31, 2015, five customers of the Contract Research segment, all various agencies of the U.S. Government, each represented more than 10% of the total segment revenue. For the three months ended December 31, 2015 and 2014, these customers made up 76 74 Geographic Financial Information Three Months Ended Three Months Ended December 31, 2015 December 31, 2014 Geographic Location Revenue % of Total Revenue % of Total United States $ 8,235,000 74 % $ 7,682,000 80 % Europe 2,041,000 18 % 884,000 9 % Other 928,000 8 % 1,045,000 11 % $ 11,204,000 100 % $ 9,611,000 100 %

Income Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 11 - Income Taxes Dynasil Corporation of America and its wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns. The Company’s U.K. subsidiary files tax returns in the U.K. The Company uses the asset and liability approach to account for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates, and tax laws, in the respective tax jurisdiction then in effect. In assessing the ability to realize the net deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the Company’s recent losses and uncertainty of future profits, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need for a full valuation allowance against its U.S. net deferred tax assets. The Company applies the authoritative provisions related to accounting for uncertainty in income taxes. As required by these provisions, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with the relevant tax authority. As of December 31, 2015 and September 30, 2015, the Company has no unrecorded liabilities for uncertain tax positions. Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense in the accompanying consolidated statement of operations. As of December 31, 2015 and September 30, 2015, the Company had no accrued interest or penalties related to uncertain tax positions. The Company currently has no federal or state tax examinations in progress. The effective tax rates were 25 0.57 34 The Company files its tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The Company’s tax filings for federal and state jurisdictions for the tax years beginning with 2012 are still subject to examination.

Settlement of Pension Liability

Settlement of Pension Liability	3 Months Ended
	Dec. 31, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule Of Defined Benefit Plans Disclosure [Text Block]	Note 12 – Settlement of Pension Liability On December 1, 2014, the Company terminated and settled its pension liability with each of the remaining participants in the EMF Defined Benefit Plan (the “Plan”). The Plan had been frozen since 2006. The total benefit payments made upon termination were $ 675,000 320,000

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 13 – Subsequent Events On February 1, 2016, the Company entered into a $ 2,000,000 2,000,000 4.5 2 3,819,000

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories, net of reserves, consists of the following: December 31, September 30, 2015 2015 Raw Materials $ 1,883,000 $ 1,828,000 Work-in-Process 847,000 862,000 Finished Goods 522,000 376,000 $ 3,252,000 $ 3,066,000

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intangible assets at December 31, 2015 and September 30, 2015 consist of the following: Useful Gross Accumulated December 31, 2015 Life (years) Amount Amortization Net Acquired Customer Base 5 to 15 $ 807,000 $ 473,000 $ 334,000 Know How 15 512,000 256,000 256,000 Trade Names Indefinite 310,000 - 310,000 Patents 20 254,000 2,000 252,000 Biomedical Technologies 5 260,000 215,000 45,000 $ 2,143,000 $ 946,000 $ 1,197,000 Useful Gross Accumulated September 30, 2015 Life (years) Amount Amortization Net Acquired Customer Base 5 to 15 $ 824,000 $ 464,000 $ 360,000 Know How 15 512,000 248,000 264,000 Trade Names Indefinite 318,000 - 318,000 Patents 20 223,000 - 223,000 Biomedical Technologies 5 260,000 200,000 60,000 $ 2,137,000 $ 912,000 $ 1,225,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense for each of the next five fiscal years and thereafter is as follows: 2016 (9 months) 2017 2018 2019 2020 Thereafter Total Acquired Customer Base $ 60,000 $ 80,000 $ 80,000 $ 80,000 $ 34,000 $ - $ 334,000 Know How 26,000 34,000 34,000 34,000 34,000 94,000 256,000 Patents 5,000 6,000 6,000 6,000 6,000 61,000 90,000 Biomedical Technologies 45,000 - - - - - 45,000 $ 136,000 $ 120,000 $ 120,000 $ 120,000 $ 74,000 $ 155,000 $ 725,000

Earnings (Loss) Per Common Sh22

Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The computation of the weighted shares outstanding for the three months ended December 31 is as follows: December 31, 2015 December 31, 2014 Weighted average shares outstanding Basic 16,551,197 16,300,902 Effect of dilutive securities Stock Options - - Restricted Stock 27,437 - Dilutive Average Shares Outstanding 16,578,634 16,300,902

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Dec. 31, 2015
Schedule Of Stock Compensation Expense [Table Text Block]	Stock Compensation Expense for the three months ended December 31, 2015 and 2014 is as follows: Three Months Ended Three Months Ended Stock Compensation Expense December 31, 2015 December 31, 2014 Stock Grants $ 83,000 $ 57,000 Restricted Stock Grants 8,000 7,000 Option Grants 6,000 - Employee Stock Purchase Plan 1,000 1,000 Subsidiary Option Grants 21,000 - Total $ 119,000 $ 65,000
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	A summary of restricted stock activity for the three months ended December 31, 2015 is presented below: Restricted Stock Activity for the Three Months ended Weighted-Average December 31, 2015 Shares Grant-Date Fair Value Nonvested at September 30, 2015 27,000 $ 1.04 Granted 40,000 1.70 Vested - - Cancelled - - Nonvested at December 31, 2015 67,000 $ 1.43
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	A summary of Xcede stock option activity for the three months ended December 31, 2015 is presented below: Weighted Average Weighted Average Options Exercise Price per Remain Contractual Outstanding Share Term (in Years) Balance at September 30, 2015 780,258 $ 1.00 8.85 Outstanding and exercisable at September 30, 2015 180,293 $ 1.00 8.50 Granted 75,000 $ 1.00 Exercised - - Cancelled (35,000) $ 1.00 Balance at December 31, 2015 820,258 $ 1.00 8.70 Outstanding and exercisable at December 31, 2015 201,512 $ 1.00 8.21
Stock Option Grants [Member]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	A summary of stock option activity for the three months ended December 31, 2015 is presented below: Weighted Average Weighted Average Options Exercise Price per Remain Contractual Outstanding Share Term (in Years) Balance at September 30, 2015 58,212 $ 2.28 1.96 Outstanding and exercisable at September 30, 2015 58,212 $ 2.28 1.96 Granted - - Exercised - - Cancelled - - Balance at December 31, 2015 58,212 $ 2.28 1.71 Outstanding and exercisable at December 31, 2015 58,212 $ 2.28 1.71
Subsidiary Option Grants [Member]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted average assumptions for grants during the three months ended December 31, 2015 used in the Black-Scholes option pricing model were as follows: Expected term in years 10 years Risk-free interest rate 2.05 % Expected volatility 82.42 % Expected dividend yield 0.00 %

Segment, Customer and Geograp24

Segment, Customer and Geographical Reporting (Tables)	3 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The Company’s segment information for the three months ended December 31, 2015 and 2014 is summarized below: Results of Operations for the Three Months Ended December 31, 2015 Contract Optics Research Biomedical Total Revenue $ 6,214,000 $ 4,990,000 $ - $ 11,204,000 Gross Profit 2,110,000 1,855,000 - 3,965,000 GM % 34.0 % 37.2 % - 35.4 % SG&A 1,751,000 1,706,000 348,000 3,805,000 Gain on sale of assets 4,000 - - 4,000 Operating Income (Loss) 363,000 149,000 (348,000) 164,000 Depreciation and Amortization 228,000 80,000 17,000 325,000 Capital expenditures 565,000 7,000 31,000 603,000 Intangibles, Net 644,000 256,000 297,000 1,197,000 Goodwill 1,155,000 4,939,000 - 6,094,000 Total Assets $ 16,506,000 $ 8,273,000 $ 857,000 $ 25,636,000 Results of Operations for the Three Months Ended December 31, 2014 Contract Optics Research Biomedical Total Revenue $ 4,948,000 $ 4,663,000 $ - $ 9,611,000 Gross Profit 1,495,000 2,098,000 - 3,593,000 GM % 30.2 % 45.0 % - 37.4 % SG&A 2,091,000 1,881,000 235,000 4,207,000 Gain on sale of assets 185,000 - - 185,000 Operating Income (Loss) (410,000) 216,000 (235,000) (429,000) Depreciation and Amortization 204,000 74,000 15,000 293,000 Capital expenditures 244,000 - - 244,000 Intangibles, Net 752,000 290,000 229,000 1,271,000 Goodwill 1,232,000 4,939,000 - 6,171,000 Total Assets $ 15,419,000 $ 9,036,000 $ 922,000 $ 25,377,000
Schedule Of Segment Revenue By Geographical Location [Table Text Block]	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended December 31, 2015 and 2014 are as follows: Three Months Ended Three Months Ended December 31, 2015 December 31, 2014 Geographic Location Revenue % of Total Revenue % of Total United States $ 8,235,000 74 % $ 7,682,000 80 % Europe 2,041,000 18 % 884,000 9 % Other 928,000 8 % 1,045,000 11 % $ 11,204,000 100 % $ 9,611,000 100 %

Adoption of Accounting Pronou25

Adoption of Accounting Pronouncements (Details Textual)	1 Months Ended
	Oct. 31, 2015USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt Issuance Cost	$ 12,000

Acquisitions and Divestitures (

Acquisitions and Divestitures (Details Textual) $ in Millions	3 Months Ended
	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Gain (Loss) on Disposition of Business	$ 0.2

Xcede Technologies, Inc. Join27

Xcede Technologies, Inc. Joint Venture (Details Textual) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2013	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Proceeds from Convertible Debt	$ 2.4
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 3
Capital Stock Financing Discount Percentage		20.00%
Common Stock Valuation		$ 5
Equity Method Investment, Ownership Percentage		90.00%

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Inventory Current [Line Items]
Raw Materials	$ 1,883,000	$ 1,828,000
Work-in-Process	847,000	862,000
Finished Goods	522,000	376,000
Inventory, Net, Total	$ 3,252,000	$ 3,066,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 2,143,000	$ 2,137,000
Accumulated Amortization	946,000	912,000
Net	1,197,000	1,225,000	$ 1,271,000
Acquired Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	807,000	824,000
Accumulated Amortization	473,000	464,000
Net	$ 334,000	$ 360,000
Acquired Customer Base [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	5 years	5 years
Acquired Customer Base [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	15 years	15 years
Know How [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	15 years	15 years
Gross Amount	$ 512,000	$ 512,000
Accumulated Amortization	256,000	248,000
Net	256,000	264,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	310,000	318,000
Accumulated Amortization	0	0
Net	$ 310,000	$ 318,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	20 years	20 years
Gross Amount	$ 254,000	$ 223,000
Accumulated Amortization	2,000	0
Net	$ 252,000	$ 223,000
Biomedical Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	5 years	5 years
Gross Amount	$ 260,000	$ 260,000
Accumulated Amortization	215,000	200,000
Net	$ 45,000	$ 60,000

Intangible Assets (Details 1)

Intangible Assets (Details 1)	Dec. 31, 2015USD ($)
Finite-Lived Intangible Assets [Line Items]
2016 (9 months)	$ 136,000
2,017	120,000
2,018	120,000
2,019	120,000
2,020	74,000
Thereafter	155,000
Total	725,000
Acquired Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
2016 (9 months)	60,000
2,017	80,000
2,018	80,000
2,019	80,000
2,020	34,000
Thereafter	0
Total	334,000
Know How [Member]
Finite-Lived Intangible Assets [Line Items]
2016 (9 months)	26,000
2,017	34,000
2,018	34,000
2,019	34,000
2,020	34,000
Thereafter	94,000
Total	256,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2016 (9 months)	5,000
2,017	6,000
2,018	6,000
2,019	6,000
2,020	6,000
Thereafter	61,000
Total	90,000
Biomedical Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
2016 (9 months)	45,000
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Total	$ 45,000

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 44,000	$ 43,000

Earnings (Loss) Per Common Sh32

Earnings (Loss) Per Common Share (Details) - shares	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Weighted average shares outstanding
Basic	16,551,197	16,300,902
Effect of dilutive securities
Dilutive Average Shares Outstanding	16,578,634	16,300,902
Employee Stock Option [Member]
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0
Restricted Stock [Member]
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	27,437	0

Earnings (Loss) Per Common Sh33

Earnings (Loss) Per Common Share (Details Textual)	3 Months Ended
	Dec. 31, 2015shares
Earnings Loss Per Common Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,212
Restricted Stock [Member]
Earnings Loss Per Common Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	27,437

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock Based Compensation [Line Items]
Stock Compensation Expense	$ 119,000	$ 65,000
Stock Grants [Member]
Stock Based Compensation [Line Items]
Stock Compensation Expense	83,000	57,000
Restricted Stock Grants [Member]
Stock Based Compensation [Line Items]
Stock Compensation Expense	8,000	7,000
Option Grants [Member]
Stock Based Compensation [Line Items]
Stock Compensation Expense	6,000	0
Employee Stock Purchase Plan [Member]
Stock Based Compensation [Line Items]
Stock Compensation Expense	1,000	1,000
Subsidiary Option Grants [Member]
Stock Based Compensation [Line Items]
Stock Compensation Expense	$ 21,000	$ 0

Stock Based Compensation (Det35

Stock Based Compensation (Details 1) - Restricted Stock [Member]	3 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Nonvested Beginning Balance | shares	27,000
Shares, Granted | shares	40,000
Shares, Vested | shares	0
Shares, Cancelled | shares	0
Shares, Nonvested Ending Balance | shares	67,000
Weighted-Average Grant-Date Fair Value, Nonvested, Beginning Balance | $ / shares	$ 1.04
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	1.7
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	0
Weighted-Average Grant-Date Fair Value, Cancelled | $ / shares	0
Weighted-Average Grant-Date Fair Value, Nonvested, Ending Balance | $ / shares	$ 1.43

Stock Based Compensation (Det36

Stock Based Compensation (Details 2) - $ / shares	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015
Stock Option Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance,Options Outstanding	58,212
Outstanding and exercisable,Options Outstanding	58,212	58,212
Granted,Options Outstanding	0
Exercised,Options Outstanding	0
Cancelled, Options Outstanding	0
Balance,Options Outstanding	58,212	58,212
Balance,Weighted Average Exercise Price per Share	$ 2.28
Outstanding and exercisable,Weighted Average Exercise Price per Share	2.28	$ 2.28
Granted,Weighted Average Exercise Price per Share	0
Exercised,Weighted Average Exercise Price per Share	0
Cancelled,Weighted Average Exercise Price per Share	0
Balance,Weighted Average Exercise Price per Share	$ 2.28	$ 2.28
Balance,Weighted Average Remain Contractual Term (in Years)	1 year 8 months 16 days	1 year 11 months 16 days
Outstanding and exercisable,Weighted Average Remain Contractual Term (in Years)	1 year 8 months 16 days	1 year 11 months 16 days
Subsidiary Option Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance,Options Outstanding	780,258
Outstanding and exercisable,Options Outstanding	201,512	180,293
Granted,Options Outstanding	75,000
Exercised,Options Outstanding	0
Cancelled, Options Outstanding	(35,000)
Balance,Options Outstanding	820,258	780,258
Balance,Weighted Average Exercise Price per Share	$ 1
Outstanding and exercisable,Weighted Average Exercise Price per Share	1	$ 1
Granted,Weighted Average Exercise Price per Share	1
Exercised,Weighted Average Exercise Price per Share	0
Cancelled,Weighted Average Exercise Price per Share	1
Balance,Weighted Average Exercise Price per Share	$ 1	$ 1
Balance,Weighted Average Remain Contractual Term (in Years)	8 years 8 months 12 days	8 years 10 months 6 days
Outstanding and exercisable,Weighted Average Remain Contractual Term (in Years)	8 years 2 months 16 days	8 years 6 months

Stock Based Compensation (Det37

Stock Based Compensation (Details 3) - Subsidiary Option Grants [Member]	3 Months Ended
	Dec. 31, 2015
Class of Stock [Line Items]
Expected term in years	10 years
Risk-free interest rate	2.05%
Expected volatility	82.42%
Expected dividend yield	0.00%

Stock Based Compensation (Det38

Stock Based Compensation (Details Textual)	3 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Subsidiary Option Grants [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 1
Subsidiary Option Grants [Member] | Xcede joint venture [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 195,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 82,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	19 months
Employee Stock Plan [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 86,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	18 months

Segment, Customer and Geograp39

Segment, Customer and Geographical Reporting (Details) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 11,204,000	$ 9,611,000
Gross Profit	$ 3,965,000	$ 3,593,000
GM %	35.40%	37.40%
SG&A	$ 3,805,000	$ 4,207,000
Gain on sale of assets	4,000	185,000
Operating Income (Loss)	164,000	(429,000)
Depreciation and Amortization	325,000	293,000
Capital expenditures	603,000	244,000
Intangibles, Net	1,197,000	1,271,000	$ 1,225,000
Goodwill	6,094,000	6,171,000	6,131,000
Total Assets	25,636,000	25,377,000	$ 24,462,000
Contract Research [Member]
Segment Reporting Information [Line Items]
Revenue	4,990,000	4,663,000
Gross Profit	$ 1,855,000	$ 2,098,000
GM %	37.20%	45.00%
SG&A	$ 1,706,000	$ 1,881,000
Gain on sale of assets	0	0
Operating Income (Loss)	149,000	216,000
Depreciation and Amortization	80,000	74,000
Capital expenditures	7,000	0
Intangibles, Net	256,000	290,000
Goodwill	4,939,000	4,939,000
Total Assets	8,273,000	9,036,000
Optics [Member]
Segment Reporting Information [Line Items]
Revenue	6,214,000	4,948,000
Gross Profit	$ 2,110,000	$ 1,495,000
GM %	34.00%	30.20%
SG&A	$ 1,751,000	$ 2,091,000
Gain on sale of assets	4,000	185,000
Operating Income (Loss)	363,000	(410,000)
Depreciation and Amortization	228,000	204,000
Capital expenditures	565,000	244,000
Intangibles, Net	644,000	752,000
Goodwill	1,155,000	1,232,000
Total Assets	16,506,000	15,419,000
Biomedical [Member]
Segment Reporting Information [Line Items]
Revenue	0	0
Gross Profit	$ 0	$ 0
GM %	0.00%	0.00%
SG&A	$ 348,000	$ 235,000
Gain on sale of assets	0	0
Operating Income (Loss)	(348,000)	(235,000)
Depreciation and Amortization	17,000	15,000
Capital expenditures	31,000	0
Intangibles, Net	297,000	229,000
Goodwill	0	0
Total Assets	$ 857,000	$ 922,000

Segment, Customer and Geograp40

Segment, Customer and Geographical Reporting (Details 1) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 11,204,000	$ 9,611,000
% of Total	100.00%	100.00%
United State [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 8,235,000	$ 7,682,000
% of Total	74.00%	80.00%
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 2,041,000	$ 884,000
% of Total	18.00%	9.00%
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 928,000	$ 1,045,000
% of Total	8.00%	11.00%

Segment, Customer and Geograp41

Segment, Customer and Geographical Reporting (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting [Line Items]
Segment Reporting Information Net Assets		$ 0.3
Sales Revenue, Segment [Member]
Segment Reporting [Line Items]
Concentration Risk, Percentage	76.00%	74.00%
Customer Five [Member] | Sales Revenue, Segment [Member]
Segment Reporting [Line Items]
Concentration Risk, Percentage	10.00%
Optics [Member] | Maximum [Member]
Segment Reporting [Line Items]
Concentration Risk, Percentage		21.00%
Optics [Member] | Minimum [Member]
Segment Reporting [Line Items]
Concentration Risk, Percentage		9.00%
Optics [Member] | Customer One [Member]
Segment Reporting [Line Items]
Concentration Risk, Percentage	10.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax [Line Items]
Effective Income Tax Rate Reconciliation, Percent, Total	25.00%	(0.57%)
Federal [Member]
Income Tax [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%

Settlement of Pension Liabili43

Settlement of Pension Liability (Details Textual)	1 Months Ended
	Dec. 31, 2014USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefits Paid	$ 675,000
Defined Benefit Plan, Settlements, Benefit Obligation	320,000
Defined Benefit Plan, Funded Status of Plan, Total	$ 355,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Feb. 01, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Middlesex Savings Bank [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Short-term Debt, Total	$ 2,000,000
Debt Conversion, Converted Instrument, Amount	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Debt Instrument, Term	5 years
Middlesex Savings Bank [Member] | Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Long-term Line of Credit	$ 2,000,000
Middlesex Savings Bank [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Long-term Line of Credit	$ 3,819,000